Home > Publikationen > 2015 > 26516172

Improved outcome with repeated intracoronary injection of bone marrow-derived cells within a registry: rationale for the randomized outcome trial REPEAT.

Assmus B, Alakmeh S, De Rosa S, Bönig H, Hermann E, Levy WC, Dimmeler S, Zeiher AM
European heart journal 2015

Zusammenfassung

Regenerative therapies have evolved as a promising new option in the treatment of post-infarction heart failure. A major limitation of intracoronary application of autologous bone marrow-derived mononuclear cells (BM-MNCs) is that homing of the applied cells is profoundly reduced in patients with post-infarction heart failure compared with patients with acute myocardial infarction. However, early pilot and also randomized controlled trials have demonstrated significant improvements in overall cardiac function. The aim of the present analysis was to quantify a potential mortality risk reduction and reduced hospitalization in order to provide data for a prospective outcome trial.

Zugehörigkeit: Division of Cardiology, Department of Medicine III, Goethe University Frankfurt, Theodor-Stern-Kai 7, Frankfurt 60590, Germany German Center for Cardiovascular Research DZHK, Partner Site Frankfurt Rhine-Main, Berlin, Germany b.assmus@em.uni-frankfurt.de.

Aritkel auf PubMed

Logo: Paul-Ehrlich-Institut Logo: Georg Speyer Haus Logo: Goethe Universität Logo: Max-Planck-Institut Logo: DRK Blutspendedienst